NASDAQ:CGTX Cognition Therapeutics Q2 2026 Earnings Results & Report $0.78 -0.03 (-3.12%) Closing price 04:00 PM EasternExtended Trading$0.78 +0.01 (+0.81%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cognition Therapeutics beat analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.04 versus the -$0.0633 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeAfter Market ClosesConference Call4:00 PM ET Cognition Therapeutics EPS ResultsActual EPS-$0.04Consensus EPS -$0.0633Beat/MissBeat by +$0.0233One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersCognition Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$5.00 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCognition Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cognition Therapeutics Q2 2026 Earnings FAQ Did Cognition Therapeutics beat earnings estimates for Q2 2026? Cognition Therapeutics (NASDAQ:CGTX) reported earnings of -$0.04 per share for Q2 2026, beating the consensus estimate of -$0.0633. The report was announced on Thursday, August 6, 2026. When is Cognition Therapeutics' next earnings date? Cognition Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cognition Therapeutics on the company's earnings history page. Cognition Therapeutics Earnings HeadlinesCognition Therapeutics secures US patent for Zervimesine through 2045 ahead of planned Phase 3 developmentOctober 13 at 8:58 AM | msn.comCognition Therapeutics Announces USPTO Patent Grant for Novel Crystalline Form of Lead Candidate Zervimesine October 13 at 6:31 AM | quiverquant.comQFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 14 at 1:00 AM | Weiss Ratings (Ad)Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045October 13 at 6:00 AM | globenewswire.comCognition Therapeutics (NASDAQ:CGTX) Stock Falls 2% - What's Next?October 11 at 9:21 AM | americanbankingnews.comCognition Set For Type C FDA Meeting In Oct '26 On Planned Phase 3 For Dementia Drug ZervimesineSeptember 29, 2026 | rttnews.comSee More Cognition Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cognition Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cognition Therapeutics and other key companies, straight to your email. Email Address About Cognition TherapeuticsCognition Therapeutics (NASDAQ:CGTX) is a clinical-stage biopharmaceutical company focused on developing medicines for neurodegenerative diseases that affect memory, cognition and behavior. The company’s research centers on drug candidates designed to protect or restore synaptic function, which is important for communication between nerve cells. Cognition Therapeutics’ lead investigational product is CT1812, an orally administered, brain-penetrant small molecule designed to modulate the sigma-2 receptor complex. The company is evaluating CT1812 as a potential treatment for Alzheimer’s disease and dementia with Lewy bodies, including through clinical studies intended to assess its effects on cognition and disease-related biological processes. The company’s programs remain investigational, and CT1812 has not been approved for commercial use. Cognition Therapeutics conducts its development activities through clinical research programs and collaborations primarily focused on neurodegenerative diseases in the United States and other study locations.View Cognition Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
